Iradimed Co Stock Performance

IRMD Stock  USD 99.81  0.03  0.03%   
On a scale of 0 to 100, Iradimed holds a performance score of 12. The company retains a Market Volatility (i.e., Beta) of 0.47, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Iradimed's returns are expected to increase less than the market. However, during the bear market, the loss of holding Iradimed is expected to be smaller as well. Please check Iradimed's potential upside, rate of daily change, and the relationship between the sortino ratio and skewness , to make a quick decision on whether Iradimed's current trending patterns will revert.

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Iradimed Co are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of rather fragile primary indicators, Iradimed exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
(0.03)
Five Day Return
4.13
Year To Date Return
4.51
Ten Year Return
485.74
All Time Return
908.18
Forward Dividend Yield
0.008
Payout Ratio
0.5561
Forward Dividend Rate
0.8
Dividend Date
2025-12-30
Ex Dividend Date
2026-02-23
1
Disposition of 1816 shares by Roger Susi of Iradimed at 86.12 subject to Rule 16b-3
11/18/2025
2
Disposition of 1000 shares by Hawkins James B of Iradimed at 88.0 subject to Rule 16b-3
11/20/2025
3
Disposition of 886 shares by Roger Susi of Iradimed at 91.01 subject to Rule 16b-3
11/24/2025
 
Iradimed dividend paid on 25th of November 2025
11/25/2025
4
Disposition of 1197 shares by Allen Monty K of Iradimed subject to Rule 16b-3
12/05/2025
5
Disposition of 3000 shares by Hawkins James B of Iradimed at 96.6125 subject to Rule 16b-3
12/09/2025
6
Disposition of 731 shares by Roger Susi of Iradimed at 97.13 subject to Rule 16b-3
12/15/2025
7
IRADIMED Assessing Valuation After Strong MultiYear Share Price Gains
12/17/2025
 
Iradimed dividend paid on 30th of December 2025
12/30/2025
8
Disposition of 996 shares by Jeff Chiprin of Iradimed subject to Rule 16b-3
01/02/2026
9
Disposition of 112 shares by Roger Susi of Iradimed at 98.15 subject to Rule 16b-3
01/12/2026
10
iRadimed Corporation Short Interest Update
01/20/2026
11
Disposition of 661 shares by Roger Susi of Iradimed at 101.38 subject to Rule 16b-3
01/26/2026
12
Ranger Investment Management L.P. Lowers Stake in iRadimed Corporation IRMD
02/06/2026
13
iRadimed Q4 2025 Earnings Preview
02/09/2026
14
iRadimed Corporation to Issue Quarterly Dividend of 0.20
02/10/2026
15
IRadimed Corporation Q4 2025 Earnings Call Transcript
02/11/2026
16
Disposition of 1000 shares by Allen Monty K of Iradimed at 100.2563 subject to Rule 16b-3
02/13/2026
Begin Period Cash Flow49.8 M
Total Cashflows From Investing Activities-8.8 M

Iradimed Relative Risk vs. Return Landscape

If you would invest  8,498  in Iradimed Co on November 16, 2025 and sell it today you would earn a total of  1,483  from holding Iradimed Co or generate 17.45% return on investment over 90 days. Iradimed Co is currently generating 0.2803% in daily expected returns and assumes 1.8377% risk (volatility on return distribution) over the 90 days horizon. In different words, 16% of stocks are less volatile than Iradimed, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Iradimed is expected to generate 2.39 times more return on investment than the market. However, the company is 2.39 times more volatile than its market benchmark. It trades about 0.15 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.13 per unit of risk.

Iradimed Target Price Odds to finish over Current Price

The tendency of Iradimed Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 99.81 90 days 99.81 
about 21.56
Based on a normal probability distribution, the odds of Iradimed to move above the current price in 90 days from now is about 21.56 (This Iradimed Co probability density function shows the probability of Iradimed Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Iradimed has a beta of 0.47. This usually indicates as returns on the market go up, Iradimed average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Iradimed Co will be expected to be much smaller as well. Additionally Iradimed Co has an alpha of 0.2135, implying that it can generate a 0.21 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Iradimed Price Density   
       Price  

Predictive Modules for Iradimed

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Iradimed. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
98.0099.84101.68
Details
Intrinsic
Valuation
LowRealHigh
89.83115.06116.90
Details
2 Analysts
Consensus
LowTargetHigh
109.20120.00133.20
Details
Earnings
Estimates (0)
LowProjected EPSHigh
0.440.450.45
Details

Iradimed Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Iradimed is not an exception. The market had few large corrections towards the Iradimed's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Iradimed Co, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Iradimed within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.21
β
Beta against Dow Jones0.47
σ
Overall volatility
5.31
Ir
Information ratio 0.1

Iradimed Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Iradimed for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Iradimed can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
About 37.0% of the company shares are held by company insiders
On 30th of December 2025 Iradimed paid $ 0.5 per share dividend to its current shareholders
Latest headline from MacroaxisInsider: Disposition of 1000 shares by Allen Monty K of Iradimed at 100.2563 subject to Rule 16b-3

Iradimed Fundamentals Growth

Iradimed Stock prices reflect investors' perceptions of the future prospects and financial health of Iradimed, and Iradimed fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Iradimed Stock performance.

About Iradimed Performance

By analyzing Iradimed's fundamental ratios, stakeholders can gain valuable insights into Iradimed's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Iradimed has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Iradimed has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 202.28  164.78 
Return On Tangible Assets 0.23  0.17 
Return On Capital Employed 0.28  0.24 
Return On Assets 0.22  0.17 
Return On Equity 0.25  0.20 

Things to note about Iradimed performance evaluation

Checking the ongoing alerts about Iradimed for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Iradimed help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
About 37.0% of the company shares are held by company insiders
On 30th of December 2025 Iradimed paid $ 0.5 per share dividend to its current shareholders
Latest headline from MacroaxisInsider: Disposition of 1000 shares by Allen Monty K of Iradimed at 100.2563 subject to Rule 16b-3
Evaluating Iradimed's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Iradimed's stock performance include:
  • Analyzing Iradimed's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Iradimed's stock is overvalued or undervalued compared to its peers.
  • Examining Iradimed's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Iradimed's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Iradimed's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Iradimed's stock. These opinions can provide insight into Iradimed's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Iradimed's stock performance is not an exact science, and many factors can impact Iradimed's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Iradimed Stock analysis

When running Iradimed's price analysis, check to measure Iradimed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iradimed is operating at the current time. Most of Iradimed's value examination focuses on studying past and present price action to predict the probability of Iradimed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iradimed's price. Additionally, you may evaluate how the addition of Iradimed to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Fundamental Analysis
View fundamental data based on most recent published financial statements